Organigram (OGI) Q4 2025 earnings review
Record Revenue & Share Gains, But Cash Flow Turns Negative
Organigram delivered a blowout quarter on the top line, with Net Revenue surging 79% YoY to $80.1M, driven by the Motif acquisition and a 173% explosion in international sales for the year. Operational profitability followed suit, with Adjusted EBITDA jumping 68% to $9.8M. However, the growth came at a cost to liquidity: Operating Cash Flow flipped to negative $1.5M due to heavy working capital investment, and the Net Loss widened significantly to $38M due to non-cash fair value adjustments on derivative liabilities.
🐂 Bull Case
International revenue is no longer a sideline; it reached a record $26.3M in FY25 (+173% YoY). This high-margin channel is becoming a primary growth engine, with German exports and Australian market entry ramping up.
Organigram has cemented its status as Canada's #1 LP with 11.9% market share. The integration of Motif (pre-rolls/vapes) is paying off, driving a 79% revenue increase and capturing leadership in the largest product categories.
🐻 Bear Case
Despite record sales, operating cash flow turned negative ($1.5M outflow) in Q4, a sharp reversal from +$8.9M a year ago. Working capital requirements for the expanded footprint are eating into liquidity, with cash position dropping 37% YoY to $84.4M.
The company's U.S. strategy faces an existential threat. New legislation (amendment to 2018 Farm Bill) could ban hemp-derived THC products. If enacted, Organigram admits it may have to 'wind-down' its newly acquired U.S. operations by Nov 2026.
⚖️ Verdict: 🟢
Bullish. The operational execution is undeniably strong: market share is up, revenue is accelerating, and EBITDA margins are expanding. The cash burn is a concern but appears to be a function of growth investment rather than structural unprofitability. The main overhang is the non-operational noise in Net Income.
Key Themes
International Segment Acceleration
Accelerating. International revenue hit a record $26.3M for FY25, up 173% YoY. In Q4 alone, the mix shift towards international sales helped drive Adjusted Gross Margin to 38%. With the EU-GMP audit completed in Nov 2024, certification could unlock further pricing power and direct-to-market efficiency in Germany.
Margin Expansion via Synergies
Accelerating. Adjusted Gross Margin reached 38% in Q4, up from 34% in FY24. The company has realized $7.1M of the targeted $15M in synergies from the Motif acquisition. As operations consolidate further and automation increases, management targets 40% gross margins in H2 FY26.
Working Capital Drag
Reversing. Operating cash flow fell to -$1.5M in Q4 from +$8.9M in the prior year period. While 'cash flow before working capital' remains positive ($3.1M), the massive inventory and receivables build required to support 79% revenue growth is straining near-term liquidity.
U.S. Hemp Regulation Threat
A critical legislative risk has emerged. The 'Continuing Appropriations and Extensions Act of 2026' includes provisions to redefine hemp, effectively banning the hemp-derived THC products that underpin Organigram's U.S. expansion (CPL acquisition). Management explicitly notes they may have to exit the U.S. market by late 2026 if this law holds.
Innovation: FAST Technology
Organigram launched its proprietary FAST (nano-emulsion) technology, designed for faster onset in ingestibles. This is a key differentiator in the 'mood state' edible market (e.g., 'happly' brand). This tech is being deployed across both Canadian and (current) U.S. portfolios to drive premium pricing.
Seed-Based Cultivation Efficiency
The shift to seed-based cultivation (vs cloning) is yielding results. It contributed to the largest annual harvest in company history and lower production costs. This operational shift is a key driver behind the gross margin expansion to 38%.
Other KPIs
Decelerating. Down 37% YoY from $133.4M. The decrease is driven by M&A activity (Motif/CPL) and working capital investments. While balance sheet remains healthy relative to peers, the burn rate needs to stabilize.
Reversing. A significant deterioration from a $5.4M loss in 24Q4. Importantly, this was driven by *non-cash* fair value changes in derivative liabilities and preferred shares, not operational degradation. Excluding these, the company is operationally profitable (positive EBITDA).
Stable relative to growth. Cost of sales grew 68% YoY, slower than the 79% Net Revenue growth. This positive spread indicates genuine operating leverage and efficiency gains from the Motif integration.
Guidance
Decelerating (Growth Rate). Implies ~16% YoY growth vs the 62% jump seen in FY25. However, this represents sustained double-digit organic growth atop a much larger base.
Accelerating. Improving from the 35% average in FY25. Drivers include international mix shift (higher margin), full realization of Motif synergies ($15M target), and seed-based cultivation efficiencies.
The outlook focuses on revenue and margin. In prior quarters, the goal was 'positive free cash flow,' but the Q4 slip into negative OCF makes the FY26 cash generation capability a key question mark.
Key Questions
Path to Positive Free Cash Flow
Operating cash flow turned negative in Q4 due to working capital. With revenue guiding to >$300M, at what revenue run-rate does the working capital build stabilize enough to allow for consistent positive Free Cash Flow?
U.S. Strategy Contingency
You flagged the risk of the U.S. effectively banning hemp-derived THC by Nov 2026. If this legislation passes as written, what is the financial exposure ($) regarding the write-down of the CPL acquisition and U.S. assets?
EU-GMP Certification Timing
The audit was completed in November 2024. Are there outstanding remediations required, or is this purely a regulatory waiting game? How much FY26 revenue is contingent on receiving this certification in H1?